| Genomic aberrations and survival in chronic lymphocytic leukemia H Döhner, S Stilgenbauer, A Benner, E Leupolt, A Kröber, L Bullinger, ... New England Journal of Medicine 343 (26), 1910-1916, 2000 | 4452 | 2000 |
| Genomic classification and prognosis in acute myeloid leukemia E Papaemmanuil, M Gerstung, L Bullinger, VI Gaidzik, P Paschka, ... New England Journal of Medicine 374 (23), 2209-2221, 2016 | 4376 | 2016 |
| Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia RF Schlenk, K Döhner, J Krauter, S Fröhling, A Corbacioglu, L Bullinger, ... New England Journal of Medicine 358 (18), 1909-1918, 2008 | 2128 | 2008 |
| Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia L Bullinger, K Döhner, E Bair, S Fröhling, RF Schlenk, R Tibshirani, ... New England Journal of Medicine 350 (16), 1605-1616, 2004 | 1262 | 2004 |
| Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene … K Döhner, RF Schlenk, M Habdank, C Scholl, FG Rücker, ... Blood 106 (12), 3740-3746, 2005 | 1132 | 2005 |
| V H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia A Kröber, T Seiler, A Benner, L Bullinger, E Brückle, P Lichter, ... Blood, The Journal of the American Society of Hematology 100 (4), 1410-1416, 2002 | 1107 | 2002 |
| IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 … P Paschka, RF Schlenk, VI Gaidzik, M Habdank, J Kroenke, L Bullinger, ... Journal of clinical oncology 28 (22), 3636-3643, 2010 | 1037 | 2010 |
| Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations T Rausch, DTW Jones, M Zapatka, AM Stütz, T Zichner, J Weischenfeldt, ... Cell 148 (1), 59-71, 2012 | 978 | 2012 |
| MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L KM Bernt, N Zhu, AU Sinha, S Vempati, J Faber, AV Krivtsov, Z Feng, ... Cancer cell 20 (1), 66-78, 2011 | 977 | 2011 |
| Lenalidomide induces ubiquitination and degradation of CK1α in del (5q) MDS J Krönke, EC Fink, PW Hollenbach, KJ MacBeth, SN Hurst, ND Udeshi, ... Nature 523 (7559), 183-188, 2015 | 906 | 2015 |
| A 17-gene stemness score for rapid determination of risk in acute leukaemia SWK Ng, A Mitchell, JA Kennedy, WC Chen, J McLeod, N Ibrahimova, ... Nature 540 (7633), 433-437, 2016 | 867 | 2016 |
| TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome FG Rücker, RF Schlenk, L Bullinger, S Kayser, V Teleanu, H Kett, ... Blood, The Journal of the American Society of Hematology 119 (9), 2114-2121, 2012 | 745 | 2012 |
| Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial S Stilgenbauer, A Schnaiter, P Paschka, T Zenz, M Rossi, K Döhner, ... Blood, The Journal of the American Society of Hematology 123 (21), 3247-3254, 2014 | 663 | 2014 |
| Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells C Scholl, S Fröhling, IF Dunn, AC Schinzel, DA Barbie, SY Kim, SJ Silver, ... Cell 137 (5), 821-834, 2009 | 639 | 2009 |
| Genomics of acute myeloid leukemia diagnosis and pathways L Bullinger, K Döhner, H Döhner Journal of clinical oncology 35 (9), 934-946, 2017 | 594 | 2017 |
| Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a … U Herrlinger, T Tzaridis, F Mack, JP Steinbach, U Schlegel, M Sabel, ... The lancet 393 (10172), 678-688, 2019 | 543 | 2019 |
| MYC stimulates EZH2 expression by repression of its negative regulator miR-26a S Sander, L Bullinger, K Klapproth, K Fiedler, HA Kestler, TFE Barth, ... Blood, The Journal of the American Society of Hematology 112 (10), 4202-4212, 2008 | 476 | 2008 |
| Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation RF Schlenk, S Kayser, L Bullinger, G Kobbe, J Casper, M Ringhoffer, ... Blood, The Journal of the American Society of Hematology 124 (23), 3441-3449, 2014 | 469 | 2014 |
| Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further … E Taskesen, L Bullinger, A Corbacioglu, MA Sanders, CAJ Erpelinck, ... Blood, The Journal of the American Society of Hematology 117 (8), 2469-2475, 2011 | 454 | 2011 |
| Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia MG Kharas, CJ Lengner, F Al-Shahrour, L Bullinger, B Ball, S Zaidi, ... Nature medicine 16 (8), 903-908, 2010 | 440 | 2010 |
